US regulators have approved a supplemental New Drug Application for Boehringer Ingelheim’s lung cancer drug Gilotrif for first-line treatment of patients with metastatic non-small cell lung cancer whose tumours have non-resistant epidermal growth factor receptor.
Health officials are urging the public make sure they are up to date with MMR vaccinations after outbreaks of measles were confirmed in five areas of England.
A UK startup spun out from Oxford University in 2016 currently working on a universal flu vaccine is being backed by Google parent company Alphabet.
Shire’s Adynovi has been approved for use in Europe for on-demand and prophylactic use in patients 12 years and older with the rare bleeding disorder haemophilia A.
US regulators have further expanded the scope of AstraZeneca and MSD’s Lynparza to include treatment of patients with BCRA-mutant metastatic breast cancer.
UK supermarket giant Tesco will share anonymised sales information with partner charities in a bid to help develop insight on health policy and public health programmes.
The NHS has now chosen 138 clinical entrepreneurs to design and deliver new technological solutions and innovations in healthcare, including the appointment of five healthcare scientists working on addressing conditions such as sickle cell disease and allergic reactions.
Emergency care is now in a state of emergency as missed targets reach an all-time high, bed occupancy rates surge, and flu cases increase sharply, and health chiefs warn that patients are “dying in corridors” and the system is “on its knees”.
Roche’s Ocrevus has been approved for use in Europe to treat adults with relapsing multiple sclerosis (RMS) and early primary progressive multiple sclerosis (PPMS).
Heptares Therapeutics, the UK-headquartered wholly-owned subsidiary of Japan’s Sosei Group, has formed a new drug research and development pact with Imperial College London focused on gastrointestinal disease.
The NHS Confederation has tasked the Institute for Fiscal Studies and the Health Foundation with analysing the funding needs of the UK’s health and care systems over the next 15 years.
AstraZeneca’s biologic Fasenra has been approved for use in Europe as an add-on maintenance treatment in patients with severe eosinophilic asthma.
NHS England has approved funding for more than 160 additional GP surgery-based clinical pharmacists able to offer expert medical advice and treatment to patients.
If so, you ought to know that the 2018 PharmaTimes Clinical Researcher of the Year – The Americas application process for teams has been made MUCH simpler this year, so if you thought you didn’t have enough time to enter, think again!
Cost regulators for therapies funded by the NHS in England and Wales have added MSD’s Simponi (golimumab) to the list of treatments recommended for severe non-radiographic axial spondyloarthritis.
